NetworkNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Harnessing the Power of Artificial Intelligence to Improve Clinical Outcomes
Predictive Oncology (NASDAQ: POAI), a knowledge-driven, precision-medicine company, applies its smart tumor profiling and artificial intelligence (“AI”) platform to extensive genomic and biomarker patient data sets to predict and improve clinical outcomes for cancer patients. An article discussing the company reads, “While precision medicine, sometimes referred to as personalized medicine, is a relatively new term, the idea has been around for years (http://nnw.fm/0gXRp). Defined by the U.S. National Library of Medicine as ‘an emerging approach for disease treatment and prevention that takes into account individual variability in genes, environment, and lifestyle for each person,’ the approach is gaining momentum as data sets especially in genomics have grown rapidly. Applying AI approaches to these large data sets offers the ability to more deeply analyze these data much faster and with more accurate results than previously. . . .Predictive Oncology is at the forefront of this growing trend that examines multiple factors about the patient from genomics, tumor profiles, nutrition, environmental factors, lifestyle and habits to determine a plan of action for treatment. In a recent overview (http://nnw.fm/w8W7b), POAI notes that for years, big pharma has invested tremendous resources — both financial and human — in genomics in order to understand a patient’s genome and hopefully provide more targeted treatments. However, despite the significant amount of time and money devoted to the research, success rates for such targeted therapies remain low, and adoption in clinical practice is lukewarm. It has become increasingly clear that genomics alone is not enough. . . . Enter Predictive Oncology. Competitors in the cancer field must wait at least five years to determine patient survival rates for specific treatments before they can show value in the data they have gathered. POAI, on the other hand, has vast amounts of historical data that it has been compiling for years, time-tested and proven data that can be leveraged today.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
Predictive Oncology (NASDAQ: POAI), a knowledge-driven, precision-medicine company, applies its smart tumor profiling and artificial intelligence (“AI”) platform to extensive genomic and biomarker patient data sets to predict and improve clinical outcomes for cancer patients. An article discussing the company reads, “While precision medicine, sometimes referred to as personalized medicine, is a relatively new term, the idea has been around for years (http://nnw.fm/0gXRp). Defined by the U.S. National Library of Medicine as ‘an emerging approach for disease treatment and prevention that takes into account individual variability in genes, environment, and lifestyle for each person,’ the approach is gaining momentum as data sets especially in genomics have grown rapidly. Applying AI approaches to these large data sets offers the ability to more deeply analyze these data much faster and with more accurate results than previously. . . .Predictive Oncology is at the forefront of this growing trend that examines multiple factors about the patient from genomics, tumor profiles, nutrition, environmental factors, lifestyle and habits to determine a plan of action for treatment. In a recent overview (http://nnw.fm/w8W7b), POAI notes that for years, big pharma has invested tremendous resources — both financial and human — in genomics in order to understand a patient’s genome and hopefully provide more targeted treatments. However, despite the significant amount of time and money devoted to the research, success rates for such targeted therapies remain low, and adoption in clinical practice is lukewarm. It has become increasingly clear that genomics alone is not enough. . . . Enter Predictive Oncology. Competitors in the cancer field must wait at least five years to determine patient survival rates for specific treatments before they can show value in the data they have gathered. POAI, on the other hand, has vast amounts of historical data that it has been compiling for years, time-tested and proven data that can be leveraged today.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
